Fruquintinib
- Generic Name
- Fruquintinib
- Brand Names
- Fruzaqla
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19N3O5
- CAS Number
- 1194506-26-7
- Unique Ingredient Identifier
- 49DXG3M5ZW
- Background
Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.
- Indication
本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。
- Associated Conditions
- -
- Associated Therapies
- -
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 45
- Registration Number
- NCT05993702
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT05971199
- Locations
- 🇨🇳
Guoliang Shao, Hangzhou, Zhejiang, China
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Junjie Peng
- Target Recruit Count
- 50
- Registration Number
- NCT05954429
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Shanghai 6th People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05941325
- Locations
- 🇨🇳
Shanghai No.6 People Hospital, Shanghai, Shanghai, China
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT05914610
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Sapience Therapeutics
- Target Recruit Count
- 115
- Registration Number
- NCT05848739
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05795296
- Locations
- 🇨🇳
Renji Hospital, Shanghai, China
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05771181
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT
- Conditions
- Interventions
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT05763927
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 47
- Registration Number
- NCT05643677
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.